Ankylosing Spondylitis (AS) Treatment Houston, Texas
AS is the prime example of a larger family of arthritis conditions known as spondyloarthropathies, all of which involve spinal inflammation in one form or another as well as inflammation of soft tissue structures around the joints such as tendons, ligaments and bursa. Psoriatic arthritis and reactive arthritis are other examples of spondyloarthropathies that share many features with AS (see related sections). In comparison to all of these conditions, however, AS has the greatest potential to cause restricted movement in the spine. The rate of spinal limitation and the extent of damage to other joints varies greatly from patient to patient, but AS has the capacity to introduce significant limitations and disabilities into the lives of young patients.
As pain moves up the back, the patient may become more bent over and less mobile. In severe cases, the neck also becomes stiff and less able to move. Not all patients progress this far, but AS has the potential to involve the entire spine from top to bottom, creating what is known as a “bamboo spine,” which is completely fused. In such individuals, the spine is also brittle and prone to fracturing after minor injury.
As mentioned above, tendinitis, bursitis, and inflammation of soft tissues around joints is commonly observed in AS (see Regional Pain Syndromes section). The shoulders, elbows, hips, and especially the heels are common sites of this type of inflammation. Heel pain can either be located on the back portion of the heel in the region of the “Achilles tendon” or in connective tissue on the bottom of the heel known as the plantar fascia. Symptoms in these locations may be so intense that they overshadow the lower back pain and stiffness that are the key features of AS.
X-rays are important to document the presence of inflammation in the sacroiliac joints. While these changes may take several years to be noticeable, an experienced physician is able to detect subtle abnormalities, which can confirm a diagnosis of AS. As the disease progresses, fusion of the vertebrae can also be visualized, the end result being the “bamboo spine” appearance described above. Ideally, the diagnosis of AS should be made before this complication is encountered. In patients early in the course of their disease, magnetic resonance imaging (MRI) can detect changes in the sacroiliac joint and other areas of the spine before they are apparent on x-ray.
While laboratory tests may be abnormal in AS, they are less helpful in making the diagnosis. Markers of inflammation may be elevated, but these findings are both nonspecific and not consistently observed even in active AS. Among all of the spondyloarthropathies, AS is mostly strongly associated with a genetic marker known as HLA-B27. This marker is seen in about 90% of Caucasian and 50% of Afro-American individuals with AS, but is also found in about 8% of the general population. Testing of every patient for HLA-B27, therefore, is not recommended and can be misleading. Only in cases where the suspicion for AS is high does this test help with the diagnosis.
All of the above investigations can be helpful in distinguishing AS from other more common causes of chronic lower back pain and designing a proper treatment plan.
Non-steroidal anti-inflammatory drugs (NSAIDs) are the first form of medical therapy that should be initiated for AS. These medications work directly on the inflammation of AS, as with other inflammatory diseases, and may be all that is needed for patients with mild disease. Examples of these drugs include ibuprofen and naproxen, but many doctors choose a possibly more powerful drug indomethacin, which may be more effective in the majority of AS patients. Side effects, such as stomach upset or serious bleeding or reduced kidney function may limit the use of these medications in certain individuals. The stomach side effects may be avoided by using COX-2 selective NSAIDs such as celecoxib (Celebrex) or valdecoxib (Bextra).
Disease modifying anti-rheumatic drugs (DMARDs) used in rheumatoid arthritis (RA) have also been studied in AS. Sulfasalazine (SSZ) has been shown to improve joint pain and swelling in patients who have arthritis in areas outside of the spine. Unfortunately, other DMARDs that are highly effective in RA, such as methotrexate, have not shown convincing benefit in treating arthritis in AS patients. Many of these drugs, however, as well as SSZ may reduce the frequency or severity of iritis flares in AS patients and may have some value in treating these individuals.
The most promising new therapies for treating more severe AS are known as tumor necrosis factor (TNF) inhibitors. All of these medications block the action of tumor necrosis factor, a protein in the body that is involved in many types of inflammation. When used in the treatment of AS, these drugs often dramatically reduce spinal pain and inflammation as well as symptoms in other joints. The activity of these drugs is so impressive, it is hoped that they will also alter the course of the disease and prevent complications, which future studies are expected to confirm.
Currently, etanercept (Enbrel), given as a once or twice weekly injection, is the only TNF inhibitor that is approved by the FDA for treating AS. The other two drugs in this class are infliximab (Remicade), given as an every 8 week intra-venous infusion, and adalimumab (Humira), given as an every two week injection. Both of these agents are awaiting FDA approval, but studies appear to document efficacy that is similar to Enbrel. TNF antagonists can increase one’s risk for certain infections, and patients beginning such therapies should be screened for tuberculosis before starting.
A single study suggested that pamidronate, an intravenous medication used to treat certain bone diseases, can also result in significant reduction in pain and stiffness in AS patients. The role this medication may have in treating AS is unclear, but further investigation is anticipated.
In addition to medical therapies, exercise has been shown to reduce pain and stiffness as well as improving mobility in AS patients. Specific exercises aimed at stretching the back, neck, and chest seem to be the most useful and should be performed under the supervision of a health care professional.
Recently, a panel of international experts got together to form guidelines for treating patients with AS. Their recommendations were that if a patient had spinal involvement alone, to begin with NSAIDs and to try full doses of at least two drugs in this category. If a patient had spinal disease plus arthritis of other joints, beginning NSAIDs and proceeding to SSZ if the disease is not well enough controlled was suggested. In patients failing these interventions, however, it was recommended that therapy with TNF inhibitors be considered. It is hoped that this aggressive approach will prevent spinal fusion and other complications of AS, as further studies will soon determine.